MacroGenics (MGNX) Given Daily News Impact Rating of -0.01
Headlines about MacroGenics (NASDAQ:MGNX) have trended somewhat negative this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. MacroGenics earned a news sentiment score of -0.01 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 47.3897100169756 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of MacroGenics (NASDAQ:MGNX) opened at $20.30 on Thursday. MacroGenics has a 1 year low of $14.36 and a 1 year high of $28.90.
MacroGenics (NASDAQ:MGNX) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). The firm had revenue of $1.70 million for the quarter, compared to the consensus estimate of $5.50 million. MacroGenics had a negative net margin of 1,526.55% and a negative return on equity of 69.31%. The company’s revenue for the quarter was down 48.5% on a year-over-year basis. During the same period last year, the firm earned ($0.97) earnings per share. equities research analysts forecast that MacroGenics will post -0.7 EPS for the current year.
MGNX has been the subject of a number of recent research reports. BidaskClub cut MacroGenics from a “hold” rating to a “sell” rating in a report on Monday, July 31st. ValuEngine cut MacroGenics from a “sell” rating to a “strong sell” rating in a report on Thursday, August 3rd. Zacks Investment Research cut MacroGenics from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Cowen and Company restated a “buy” rating on shares of MacroGenics in a report on Friday, August 4th. Finally, Morgan Stanley dropped their price objective on MacroGenics from $22.00 to $21.00 and set an “equal weight” rating for the company in a report on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company’s stock. MacroGenics currently has a consensus rating of “Buy” and a consensus price target of $30.10.
In other MacroGenics news, SVP Jon Marc Wigginton sold 10,000 shares of MacroGenics stock in a transaction on Wednesday, October 25th. The stock was sold at an average price of $20.00, for a total transaction of $200,000.00. Following the completion of the sale, the senior vice president now directly owns 40,000 shares of the company’s stock, valued at approximately $800,000. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 8.30% of the company’s stock.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.